Equity · Healthcare
LYEL
NASDAQLyell Immunopharma (LYEL)
The line runs 14.69 USD on 24 August through 14.38 USD on 4 September, on a scale from 14.0 to 15.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 353.5M USD
- Revenue, year to Dec 2025
- 36K USD
- EPS, diluted, year to Dec 2025
- −16.06 USD
- 52-week range
- 11 USD – 38.55 USD
- Avg volume
- 14.7K
as of Sep 4, 2026
Have Lyell Immunopharma (LYEL) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Lyell Immunopharma insiders reported 6 open-market sales and 2 purchases (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest reported trade 10 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Nov 2026 | Bulis Veronica SanchezVP, Corporate Controller | Sell | 416 | 7K USD |
| 10 Nov 2026 | Hill Stephen J.Chief Operating Officer | Sell | 88 | 1K USD |
| 10 Nov 2026 | Lee Gary K.Chief Scientific Officer | Sell | 129 | 2K USD |
| 10 Nov 2026 | Seely LynnPresident and CEO | Sell | 545 | 9K USD |
| 04 Nov 2026 | ARCH Venture Partners IX, LLC10% Owner | Buy | 2,321,262 | 25.0M USD |
| 04 Nov 2026 | ARCH Venture Fund XIII, L.P.10% Owner | Buy | 2,321,262 | 25.0M USD |
| 12 Oct 2026 | Aguirre Jarrad MattieuChief Medical Officer | Sell | 422 | 4K USD |
| 10 Sep 2026 | Shook DavidChief Medical Officer | Sell | 500 | 6K USD |
| Bought | 2 open-market purchases | 4,642,524 | $50.00M | |
| Sold | 6 open-market sales | 2,100 | $29K |
Which funds hold Lyell Immunopharma (LYEL)?
7 of the 45 institutional funds we track reported a Lyell Immunopharma position for the quarter ended 30 Sep 2026 — a combined 10.1M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | New position | 345,922 | 3.4M USD | |
| Renaissance Technologies | Added | 189,122 | 1.9M USD | +45.3% |
| Two Sigma Investments | Added | 168,122 | 1.6M USD | +217.6% |
| Millennium Management | Trimmed | 141,059 | 1.4M USD | −61.6% |
| Citadel Advisors | Added | 106,744 | 1.0M USD | +471.0% |
| Point72 Asset Management | Added | 56,992 | 558K USD | +118.5% |
| Marshall Wace | Trimmed | 18,746 | 184K USD | −82.4% |
What has been filed or recorded for Lyell Immunopharma (LYEL)?
The filings we hold for Lyell Immunopharma, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 140 shares | 2K USD notional · 0.001% of shares out |
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 81 shares | 885 USD notional · <0.001% of shares out |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 18 shares | 182 USD notional · <0.001% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,399 shares | 11K USD notional · 0.006% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 80 shares | 662 USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.86 USD | Revenue $0M |
| 30 Sep 2026 | Financials | Total assets | 273.9M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 192.7M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.92 USD | Revenue $0M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.10 USD | Revenue $0M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −16.06 USD | Revenue $0M |
| 31 Dec 2025 | Financials | Revenue | 36K USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −274.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −16.06 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −2.13 USD | Revenue $0M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −2.89 USD | Revenue $0M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −3.54 USD | Revenue $0M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −26.23 USD | Revenue $0M |
What do people ask about Lyell Immunopharma (LYEL)?
What did Lyell Immunopharma shares close at?14.38
Lyell Immunopharma closed at 14.38 USD on 4 Sep 2026, up 0.14% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Lyell Immunopharma’s market cap?353.5M
Lyell Immunopharma is worth 353.5M USD by market value as of 4 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Lyell Immunopharma’s revenue?36K
Lyell Immunopharma reported revenue of 36K USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Lyell Immunopharma insiders bought or sold shares recently?6 sales
In the 90 days to 22 Nov 2026, Lyell Immunopharma insiders reported 6 open-market sales and 2 purchases (SEC Form 4). See Insiders
Which funds own Lyell Immunopharma?7 of 45
7 of the 45 funds we track reported a Lyell Immunopharma position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Renaissance Technologies and Two Sigma Investments. See Funds
When did Lyell Immunopharma last report earnings?−1.86
Lyell Immunopharma last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.86 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words